azathioprine has been researched along with Thyrotoxicosis in 1 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Thyrotoxicosis: A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the study was to assess the influence of early immunosuppressive treatment of autoimmune thyrotoxicosis with azathioprine on the course of the disease and the incidence of its complications." | 5.11 | [Assessment of early immunosuppressive therapy in the prevention of complications of Graves' disease]. ( Gołkowski, F; Huszno, B; Plinta, T; Szybiński, Z; Trofimiuk, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huszno, B | 1 |
| Trofimiuk, M | 1 |
| Gołkowski, F | 1 |
| Plinta, T | 1 |
| Szybiński, Z | 1 |
1 trial available for azathioprine and Thyrotoxicosis
| Article | Year |
|---|---|
[Assessment of early immunosuppressive therapy in the prevention of complications of Graves' disease].
Topics: Adrenergic beta-Antagonists; Adult; Antithyroid Agents; Azathioprine; Drug Therapy, Combination; Fem | 2004 |